Merck & Co. has agreed to accumulate Cidara Therapeutics for about $9.2 billion, the businesses mentioned, in a deal designed to bolster the client’s antiviral pipeline with a Part III drug designed to stop influenza in people at greater threat of issues.
That Part III drug—Cidara’s lead pipeline candidate CD388—is a long-acting antiviral designed to attain common prevention of seasonal and pandemic influenza. CD388 consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to stop influenza A and B.
CD388 is now below research within the Part III ANCHOR trial (NCT07159763), which is assessing the drug amongst grownup and adolescent members deemed to be at greater threat of growing issues from influenza.
“We intend to construct on the Cidara crew’s exceptional progress and are assured that CD388 has the potential to be one other essential driver of progress by the subsequent decade, creating actual worth for shareholders,” Robert M. Davis, Merck’s chairman and CEO, mentioned in a press release.
Merck’s plan to accumulate Cidara comes 4 months after Cidara introduced optimistic topline outcomes from its Part IIb NAVIGATE trial (NCT06609460) exhibiting CD388 to have met all major and secondary endpoints related to stopping symptomatic laboratory-confirmed influenza in wholesome unvaccinated adults ages 18–64.
Important prevention efficacy
NAVIGATE outcomes confirmed a statistically vital prevention efficacy (PE) for every of three dose teams in people who acquired a single dose of CD388 at first of the flu season and have been evaluated for laboratory and clinically confirmed influenza over 24 weeks. PE ranged from 57.7% among the many 1,175 members given the low (150 mg) dose of CD388, to 76.1% among the many 1,187 excessive dose (450 mg) members.
The research additionally met all secondary endpoints, together with efficacy at 37.8- and 37.2-degree Celsius temperature thresholds, in addition to upkeep of PE as much as 28 weeks with statistical significance.
“Because of the extraordinary dedication of our crew, the Part IIb NAVIGATE research delivered compelling outcomes that reveal CD388’s potential to offer an extra choice to vaccines and antivirals to assist tackle unmet wants in influenza prevention,” said Jeffrey Stein, PhD, Cidara’s president and CEO. “[Merck]’s international improvement, regulatory and business capabilities present the experience and assets wanted to carry this essential innovation to these people who want it most.”
In September, Cidara launched its Part III ANCHOR trial (NCT07159763), a randomized, double-blind, placebo-controlled research designed to guage the protection and efficacy of CD388 for the prevention of influenza in adults and adolescents at greater threat of growing influenza issues.
ANCHOR’s first members have been dosed in September, with enrollment continuing in 150 websites throughout the USA and the UK. The research has a goal enrollment of 6,000 members, with plans for an interim evaluation within the first quarter of 2026 to find out the potential want for added enrollment.
Final month, Cidara gained an as much as $339.2 million award (contract quantity 75A50125C0017) from the Biomedical Superior Analysis and Growth Authority (BARDA). The award’s base interval funding of $58.1 million over an preliminary 24 months is meant to assist the manufacturing of CD388 in the USA. CD388 has additionally acquired the FDA’s Breakthrough Remedy and Quick Observe designations.
“This acquisition expands and enhances our respiratory portfolio and pipeline,” added Dean Y. Li, MD, PhD, president, Merck Analysis Laboratories.
Recouping income
The Cidara acquisition is Merck’s newest effort to recoup the billions of {dollars} in gross sales it is going to lose as its getting older blockbusters lose patent exclusivity within the coming years. These getting older blockbusters embody the multi-indication most cancers immunotherapy Keytruda® (pembrolizumab), which generated $23.303 billion within the first three quarters of this yr, on high of $29.482 billion in all of 2024—topping GEN’s A-Checklist of Prime 10 Greatest Promoting Medication, printed earlier this yr.
Additionally set to lose patent safety inside Merck’s portfolio:
- Gardasil® and Gardasil 9 [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)], $4.202 billion in Q1–Q3 2025 and $8.583 billion in 2024 (Merck stories solely mixed income for each merchandise)
- Januvia® (sitagliptin), $1.302 billion and $1.334 billion
- Janumet® and its extended-release model Janumet® XR (sitagliptin and metformin hydrochloride), $741 million and $935 million
- Lenvima® (lenvatinib), which Merck co-markets with Eisai, $781 million and $1.010 billion, recorded as “alliance” income representing Merck’s share of income (consisting of product gross sales internet of price of gross sales and commercialization prices)
- Lynparza® (olaparib), which Merck co-markets with AstraZeneca, $1.061 billion and $1.311 billion, recorded as alliance income, representing Merck’s share of income
As with different pharma giants going through the proverbial “patent cliff”, Merck is keen so as to add new remedies to its marketed portfolio and scientific pipeline.
On October 7, Merck accomplished its $10 billion buy of Verona Pharma, a deal designed to develop the pharma big’s pipeline and portfolio of cardio-pulmonary illness remedies. The deal added to Merck’s portfolio the marketed drug Ohtuvayre® (ensifentrine), which gained FDA approval final yr as a upkeep therapy for continual obstructive pulmonary illness (COPD) in adults, and is being assessed in scientific trials as a possible therapy for non-cystic fibrosis bronchiectasis.
Based mostly in San Diego, Cidara makes use of its Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics designed to inhibit particular illness targets whereas concurrently participating the immune system.
Traders roared their approval of Merck’s shopping for out Cidara by sending Cidara’s shares greater than doubling on Friday, a 105% surge that rocketed the corporate’s shares traded on NASDAQ to $217.71 on the shut of buying and selling. Merck shares on the New York Inventory Trade closed unchanged at $92.93 on Friday.
Via a subsidiary, Merck plans to accumulate all excellent shares of Cidara for $221.50 per share money—a 109% premium to Cidara’s Thursday closing worth of $105.99. The acquisition is topic to a majority of Cidara’s stockholders tendering their shares in a young supply.
The boards of Merck and Cidara have authorized the transaction. The deal is anticipated to shut within the first quarter of 2026, topic to the expiration of the ready interval below the Hart-Scott-Rodino Antitrust Enhancements Act and different customary situations.
“This milestone represents a transformational second for Cidara and for our mission to redefine influenza prevention,” Stein added.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s traits immediately: learn extra, subscribe to our e-newsletter, and turn out to be a part of the NextTech neighborhood at NextTech-news.com
